Notably, the favorable genetic-risk group comprises three distinct subtypes, namely NPM1-mutated patients without FLT3-ITD, patients with core-binding factor AML (CBF-AML), and those with CEBPAbZIP mutations. Here, CEBPZ is linked to acute myeloid leukemia.